# Cizzle Biotechnology secures US patent allowance for CIZ1B lung cancer biomarker test

- Link: https://www.directorstalkinterviews.com/cizzle-biotechnology-secures-us-patent-allowance-for-ciz1b-lung-cancer-biomarker-test/4121253578
- Published: 2026-06-12T07:30:40+01:00
- Author: Amilia Stone

**Cizzle Biotechnology Holdings plc** (LON:CIZ), the UK-based developer of diagnostic
tests for early-stage cancer, has announced that a patent application covering the
Company’s core methods to measure the CIZ1B lung cancer biomarker has now been allowed
by the U.S. Patent and Trademark Office. This additional patent further enhances
the Company’s strong patent portfolio, especially in the key market of the USA and
follows the grant of a patent in Canada, as announced on 4 February 2026.

As with the recent patent granted in Canada, the USPTO patent, ‘Use of a fibrinogen
capture agent to detect a CIZ1B variant’, concerns a two-step test format developed
by Cizzle at the University of York.  This test format is licensed to Cizzle Bio
Inc for use in North America and the Caribbean, and these new patents strengthen
BIO’s position as they prepare to launch the test and establish a robust position
for commercialising the Company’s innovative and proprietary technology.

**Background**

The CIZ1B biomarker test is the product of work by Professor Dawn Coverley, the 
Company’s founder and CSO, and her research team at the University of York, initially
supported by both UK industry and charity sector research grants.

The Company’s commercial strategy is to licence globally its proprietary test for
the CIZ1B biomarker for use in the early detection of lung cancer. As such, Cizzle
Biotechnology’s patent portfolio and technology know-how is central to securing 
future licensing and royalty revenue. Developing a strong patent portfolio in North
America is intended to enable BIO to establish a leading market position and supports
its partnership programme with specialist clinical laboratories and hospitals, enabling
market penetration to ensure the test is available to as many clinicians and patients
as possible.

Cizzle Biotechnology also has been granted patent protection from the European Patent
Office and intends to secure further licensing partnerships with accredited facilities
in the UK and Europe, including the NHS. Bringing the CIZ1B biomarker test to market
will provide valuable new solutions applicable to the current NHS cancer plan which
aims to improve cancer survival by diagnosing 75% of cancers at stages 1 and 2 by
2028.

> **Commenting, Dawn Coverley, Chief Scientific Officer of Cizzle Biotechnology,
> said:**
> “Strengthening of the Company’s patent portfolio with this grant by the USPTO 
> is timely and perfectly aligned with recent efforts to take the CIZ1B ELISA test
> format to market with our US partner Cizzle Bio Inc.”

Share on:
